Supplementary Table 2– Data requirements outlined as part of the commercial negotiation

|  |  |  |  |
| --- | --- | --- | --- |
| **Technology name** | **NICE TA/HST number** | **Type of commercial negotiation** | **Data requirements** |
| Pazopanib | TA215 | Patient access scheme: Discount + possible rebate | Details of the rebate scheme were commercial in confidence. The rebate was linked to the outcome of the head-to-head COMPARZ trial. The rebate was not activated, and guidance was re-issued after a change to the patient access scheme, which is now only based on a simple discount |
| Ataluren | HST3 | Managed access agreement | Committee required further data collection on clinical outcomes and health-related quality of life for patients and caregivers |
| Brentuximab vedotin | TA446 | Cancer Drugs Fund | Committee required further data collection on stem cell transplant rates after brentuximab vedotin treatment |
| Asfotase alfa | HST6 | Managed access agreement | Committee required further data collection on measures of growth (length/height; weight); survival; ventilation support, health-related quality of life and clinical scales (BAMF; 6MWT; Bleck score) |
| Osimertinib mesylate | TA416 | Cancer Drugs Fund | Committee required further data collection on overall survival, duration of treatment and generalisability of the trial's results to UK clinical practice |